Critical choices for critical medicines

Shortages of critical medicines can have wide-reaching consequences for patients across Europe. While European Commission’s proposed Critical Medicines Act is a positive step, its emphasis on restrictive localisation measures risk protectionism and fails to address the core issue. Instead, the focus must be on building resilient and diversified supply chains. By fostering international partnerships, supporting fair procurement practices and reducing regulatory burdens, policymakers can help safeguard patient access while strengthening Europe’s global competitiveness. Learn why a balanced, evidence-based approach to critical medicines is needed in our latest blog.